Afatinib is a second-generation epidermal growth factor receptor (EGFR) inhibitor that has been shown to be effective against EGFR-mutated non-small cell lung cancer (NSCLC) resistant to conventional EGFR inhibitors such as gefitinib and erlotinib. Although ocular side effects of gefitinib and erlotinib have been reported. those for afatinib have yet to be definitively established. Th... https://parisnaturalfoodes.shop/product-category/collagen-beauty-liquid/